Can DAA therapy for HCV reactivate HBV in coinfected patients? episode artwork

EPISODE · Feb 8, 2018 · 9 MIN

Can DAA therapy for HCV reactivate HBV in coinfected patients?

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

In this Lancet Gastroenterology & Hepatology podcast, Johannes Vermehren discusses the risks of Hepatitis B reactivation in coinfected patients receiving treatment for Hepatitis C.

NOW PLAYING

Can DAA therapy for HCV reactivate HBV in coinfected patients?

0:00 9:10

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 9 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on February 8, 2018.

What is this episode about?

In this Lancet Gastroenterology & Hepatology podcast, Johannes Vermehren discusses the risks of Hepatitis B reactivation in coinfected patients receiving treatment for Hepatitis C.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!